Table 2.
Characterizations of dose adjustment, regimen interruption, and treatment discontinuations
| Alectinib | Crizotinib | |
|---|---|---|
| Patient (count—n) | 70 | 47 |
| Dose adjustment—unique patient count (%) | 19 (27.1) | 10 (21.3) |
| Time to first dose adjustment—mean (std) | 206.6 (230.4) | 108.8 (89.6) |
| Number of dose adjustment incidences—count | 30 | 17 |
| Adverse events—count (%) | 23 (76.7) | 13 (76.5) |
| Financial toxicity—count (%) | 1 (4.3) | |
| Disease progression—count (%) | 2 (8.7) | 1 (5.9) |
| Death—count (%) | ||
| Other—count (%) | ||
| Resume to prior doses—count (%) | 4 (17.4) | 3 (17.6) |
| Regimen interruption—unique patient count (%) | 16 (22.9) | 5 (10.6) |
| Time to first regiment interruption—mean (std) | 187.8 (335.3) | 113.6 (115.5) |
| First regimen interruption duration—mean (std) | 13.1 (11.2) | 17.4 (13.4) |
| Number of regimen interruption incidences | 21 | 6 |
| Adverse events—count (%) | 18 (85.7) | 5 (83.3) |
| Financial toxicity—count (%) | 1 (4.8) | |
| Disease progression—count (%) | ||
| Death—count (%) | ||
| Other—count (%) | 2 (9.5) | 1 (16.7) |
| Treatment discontinuation—unique patient count (%) | 33 (47.1) | 40 (85.1) |
| Time to discontinuation—mean (std) | 439.5 (460.3) | 453.0 (513.7) |
| Number of treatment discontinuation incidences | 33 | 40 |
| Adverse events—count (%) | 2 (6.1) | 5 (12.5) |
| Financial toxicity—count (%) | ||
| Disease progression—count (%) | 25 (75.8) | 31 (77.5) |
| Death—count (%) | 3 (9.1) | 2 (5.0) |
| Other—count (%) | 3 (9.1) | 2 (5.0) |